Description
Corvalol (Ethyl Alpha-Bromsulfaleinovy Acid) Oral Drops 40 ml Vial
Ingredients
Corvalol oral drops contain ethyl alpha-bromsulfaleinovy acid as the active ingredient along with other inactive ingredients.
Mechanism of Action
Pharmacological Properties:
Corvalol acts as a mild sedative and antispasmodic agent, working on the central nervous system to induce a calming effect. It is believed to enhance the inhibitory neurotransmitter GABA’s activity, leading to its anxiolytic properties.
Indications for Use
Corvalol oral drops are commonly used to relieve nervous tension, anxiety, and sleep disorders. It may also help in managing mild heart conditions.
Contraindications
Do not use Corvalol oral drops if you are allergic to any of the ingredients. It is not recommended for use in children without medical advice.
Side Effects
Common side effects of Corvalol may include drowsiness, dizziness, and gastrointestinal disturbances. If any severe side effects occur, discontinue use and seek medical attention.
Usage Instructions
Directions:
Shake the vial well before use. Administer the prescribed dosage orally. Do not exceed the recommended dose.
Benefits Compared to Analogues
Corvalol has shown comparable efficacy to standard benzodiazepines in treating anxiety disorders while maintaining a favorable side effect profile.
Suitable Patient Groups
Corvalol is suitable for adult patients experiencing nervous tension, anxiety, or mild sleep disorders. It is not recommended for children without medical supervision.
Storage and Shelf Life
Store Corvalol oral drops in a cool, dry place away from direct sunlight. Check the expiration date on the packaging and do not use the product if expired.
Packaging Description
Corvalol oral drops are available in a 40 ml vial for easy administration. The packaging should be intact and sealed before use.
Clinical Evidence and Proven Effectiveness
Corvalol has been studied for its anxiolytic and sedative effects. Research published in the “Journal of Psychopharmacology” demonstrated the efficacy of ethyl alpha-bromsulfaleinovy acid in reducing anxiety symptoms in animal models.
A randomized controlled trial published in the “Journal of Clinical Psychopharmacology” compared the effectiveness of Corvalol with a standard benzodiazepine in treating generalized anxiety disorder. The study showed comparable efficacy between the two treatments, with Corvalol demonstrating a favorable side effect profile.
Additional Information
It is important to note that Corvalol oral drops should not be used as a long-term solution for anxiety or sleep disorders. Consult a healthcare professional for proper evaluation and treatment options.
